Administration of diazoxide.

TEVA GLOBAL RESPIRATORY RESEARCH LLC PROGLYCEM brand of diazoxide Capsules Suspension, USP FOR ORAL ADMINISTRATION

DESCRIPTION PROGLYCEM (diazoxide) is a nondiuretic benzothiadiazine derivative taken orally for the management of symptomatic hypoglycemia. PROGLYCEM Capsules contain 50 mg diazoxide, USP. The Suspension contains 50 mg of diazoxide, USP in each milliliter and has a chocolate-mint flavor; alcohol content is approximately 7.25%. Other ingredients: Sorbitol solution, chocolate cream flavor, propyl...

Diazoxide in von Gierke's disease.

Diazoxide in treatment of primary pulmonary hypertension.

Three patients with primary pulmonary hypertension and one man with suspected thromboembolic pulmonary hypertension were given up to 300 mg diazoxide by injection into the pulmonary artery. The three patients with primary pulmonary hypertension responded with a fall in total pulmonary resistance and a rise in cardiac output. The patient with suspected thromboembolic pulmonary hypertension did n...

Effects of diazoxide in multiple sclerosis

Objective: The aim of this study was to test the safety of diazoxide and to search for signs of efficacy in patients with relapsing-remitting multiple sclerosis (RRMS). Methods: In this multicenter, randomized, placebo-controlled, double-blind trial (treatment allocation was concealed), 102 patients with RRMS were randomized to receive a daily oral dose of diazoxide (0.3 and 4 mg/d) or placebo ...

Post-ischemic administration of diazoxide attenuates long-term microglial activation in the rat brain after permanent carotid artery occlusion.

Diazoxide is a putative mitochondrial, ATP-sensitive potassium channel opener that has been implicated in neuroprotection in cerebral ischemia. Administered as pretreatment, diazoxide can attenuate ischemia-related neuronal injury, but little is known about the potential neuroprotective properties of the drug when it is given after the onset of an ischemic insult. In a previous study, we applie...